US association warns against Alzheimer's tests:
This article was originally published in Clinica
Executive Summary
The Los Angeles Alzheimer's Association has warned against the use of new tests to assist in the diagnosis of the disease. The note of caution coincides with the release of Athena Neurosciences' ADmark Assays (see page 22). "We don't yet know for certain how to interpret these tests, or how useful they will be in diagnosing Alzheimer's disease, " says Peter Braun, executive director of the association. He confirmed the Alzheimer Association's Ronald and Nancy Reagan Research Institute plans to assemble a panel of scientists to advise the medical community and the public on new diagnostic approaches to the disease.
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.